Test 33

Deferiprone

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Deferiprone

Systematic (IUPAC) name
3-hydroxy-1,2-dimethylpyridin-4(1H)-one
Identifiers
CAS number	30652-11-0
ATC code	V03AC02
PubChem	CID 2972
ChemSpider	2866 Y
KEGG	D07416 Y
ChEMBL	CHEMBL70927 Y
Chemical data
Formula	C7H9NO2
Mol. mass	139.152 g/mol
SMILES	eMolecules & PubChem
InChI[show] InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 Y Key: TZXKOCQBRNJULO-UHFFFAOYSA-N Y
Pharmacokinetic data
Metabolism	Glucuronidation
Half-life	2 to 3 hours
Excretion	Renal (75 to 90% in 24 hours)
Therapeutic considerations
Licence data	EMA:Link
Pregnancy cat.	?
Legal status	?
Routes	Oral
Y(what is this?)  (verify)

Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.^[1]
It is currently licensed for use in Europe and Asia, but not in Canada and the United States.^[1][2]
Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.^[3]

[edit] Controversy

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.^[4] Dr. Olivieri's data suggested that deferiprone leads to progressive hepatic fibrosis, a finding which is in dispute.^[5][6]